ChromaDex appoints Crowe LLP as new independent auditor effective December 13, 2024

Niagen Bioscience, Inc.

Audit Committee approved Crowe LLP as independent auditor for fiscal year ending Dec 31, 2024, effective Dec 13, 2024.
No disagreements with prior auditor during fiscal years 2023 and 2022 and subsequent interim period.
No consultations with Crowe regarding application of accounting principles or audit opinion prior to engagement.
Change follows competitive request-for-proposal process conducted by Audit Committee.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.